Syntax, a leading global technology solutions provider driving enterprise transformation in the cloud, today announced it has received a Golden Certificate from SAP® in recognition of 10 consecutive ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), ...
A local stem cell therapy company added several new investors as part of its Series A expansion. Learn more here.
Syntax Bio expands Series A to $14.4M to boost CRISPR Cellgorithm platform and type 1 diabetes beta-cell therapy amid tough biotech funding—read more.
CHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming next generation cell therapies, today announced a research and development collaboration with Mayo Clinic focused on ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of ...